CID released the results of Demonstr8 randomised trial results at a late-breaking trials session at EuroPCR (21–24 May, Paris, France). The study, presented by principal investigator Francesco Prati, showed that the Cre8 drug-eluting stent was non-inferior to a bare metal stent with a high statistically significant difference (RUTTS Score <30%; 99.75% CRE8™ vs.99.55% BMS; p<0.0001).
According to a study presented at EuroPCR EuroPCR (21–24 May, Paris, France), the use of the Axxess drug-eluting stent for the treatment of complex coronary bifurcation lesions resulted in low levels of both major adverse cardiovascular events (MACE) and very late definite stent thrombosis over a five-year period.
Neovasc, at EuroPCR (21–24 May, Paris, France), reported initial data from open-label patient registries that are tracking the progress of refractory angina patients implanted with its Reducer device, which is a percutaneous device that is CE marked for the treatment of refractory angina.
OrbusNeich has announced that it has received the CE mark for its dual therapy coronary stent (Combo), and that it has launched the device in Europe and markets in Asia Pacific and Middle East Regions.
Las personas que toman dosis altas de unos analgésicos comunes conocidos como antiinflamatorios no esteroides (AINE) se enfrentan a un mayor riesgo de sufrir de problemas del corazón, muestra un análisis reciente.
Volcano announced preliminary results from the ADVISE (Adenosine vasodilator independent stenosis evaluation) II trial at a hotline late-breaking clinical trial session at EuroPCR (21–24 May, Paris, France). These prospective results confirm prior retrospective publications and demonstrate the clinical usefulness of an iFR/FFR hybrid approach to simplify lesion assessment and to save the use of hyperaemic drugs in a significant number of patients.
At EuroPCR 2013 in Paris, France (21–24 May), three separate analyses have addressed one of the most common clinical challenges in the treatment of complex coronary artery disease and showed that the the Resolute drug-eluting stent from Medtronic has performed strongly in coronary bifurcation lesions over the long term.
OrbusNeich today launched the world s first dual therapy stent – the COMBO Dual Therapy Stent – to address the challenges of delayed healing of the coronary artery associated with monotherapy drug eluting stents (DES), the current standard of care for the treatment of coronary artery disease (CAD). The introduction of the COMBO Stent is in conjunction with the company s receipt of a CE Mark for the product and involves a sales roll-out in Europe and selected markets in the Asia Pacific and Middle East regions.
OrbusNeich has announced that its Genous stent is associated with a significantly lower rate of binary restenosis compared to bare metal stents in low-risk no stent thrombosis segment elevation acute coronary syndrome patients at six months. Data from JACK-EPC, an investigator-initiated randomised study, were published in Minerva Cardioangiologica.
On the 22 May 2013 at EuroPCR in Paris, France, Direct Flow Medical, a transcatheter heart valve company focused on improving patient outcomes, announced that it had met its primary endpoint in the fully-enrolled, 100-patient DISCOVER CE mark trial by achieving 99% freedom from all-cause mortality at 30 days.
PLC Systems Inc. (PLCSF), a company focused on innovative medical device technologies, today announced that Dr. Vaikom Mahadevan presented RenalGuard® data during the Interventions for Structure Heart Disease session at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). The data presented supports the further development of RenalGuard Therapy® to minimize Acute Kidney Injury (AKI) in patients undergoing Transcatheter Aortic Valve Implantation (TAVI) procedures.
According to Medtronic, the Export Advance aspiration catheter has received the CE mark. The Export Advance aspiration catheter is not approved for use in the USA. The latest addition to the Export family of aspiration catheters are expected to be exhibited at EuroPCR (May 21–24, Paris, France).
Medtronic has revealed the results of a cost-effectiveness model comparing transcatheter aortic valve implantation (TAVI) with the CoreValve System to medical management. Presented at EuroPCR (21–24 May, Paris, France), the UK-based analysis compared the “real world” Medtronic CoreValve ADVANCE study to the medical management cohort of the PARTNER B study and found that the CoreValve System was cost-effective. Patients participating in this study had severe aortic stenosis and were unable to undergo surgery.
Boston Scientific Corporation (BSX) reports positive results from two trials evaluating new, innovative drug-eluting stent (DES) technologies, which are emerging treatment options for coronary heart disease. Data from the first human use NG PROMUS Clinical Trial evaluating the safety and effectiveness of the Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent System, and two-year follow-up data from the EVOLVE Trial comparing the safety and effectiveness of the SYNERGY Everolimus-Eluting Bioabsorbable Polymer-Coated Platinum Chromium Coronary Stent System to the PROMUS Element™ Stent System were presented today at the annual EuroPCR Scientific Program in Paris.
On the 21 May, at EuroPCR, Paris, France, new registry data confirmed that the BioMatrix drug-eluting stent family is safe over a 12-month period in a “real-world” population of 5559 patients.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos